

Position statement on generic and brand prescribing

It is NEL ICB policy that all NHS prescriptions should be prescribed generically unless the factors outlined below are applicable to the drug or the individual concerned.

Benefits to prescribing generically:

- 1. **Reduces risk** each drug has only one generic name, but may have many brand names, generic prescribing can reduce prescribing and dispensing errors.
- 2. Enables quicker medicine supply when medicines are prescribed generically, the pharmacist may dispense any suitable generic or branded product, which can reduce delays in supplying medicines to the patients. If a medicine is prescribed by brand name, the pharmacist may dispense only the specified brand, unless a Serious Shortage Protocol (SSP) is in place. This supports supply issues at times when there are medicine shortages.
- 3. Offers value for money it is usually more cost-effective to prescribe generically as the pharmacy is reimbursed at a set price, listed in the Drug Tariff.

Document control			
Version	1		
Produced by	Julia Taylor, NEL Pharmacy and Medicines Optimisation Team		
Approved by	North East London Formulary & Pathways Group (FPG)		
Date approved	06/06/2023		
Ratified by	North East London Integrated Medicines Optimisation & Prescribing Group (IMOC)		
Date ratified	27/06/2023		
Review date	27/06/2025		

When to prescribe by brand name (Examples given below are not an exhaustive list, please refer to the <u>BNF</u> or <u>SPS</u>):

Questions	Answers		
Does the patient have a clinically significant hypersensitivity to any of the excipients in other generic or branded versions of that same drug (same strength, release rate and dosage form).*	Yes	No	
	Prescribe the specific product the patient can tolerate	Prescribe by generic	
Is this a medicine with a narrow therapeutic index?			
e.g. lithium, phenytoin, tacrolimus	Yes	No	
	Prescribe by brand	Prescribe by generic	
Is there a difference in bioavailability between different brands of the same medicine? e.g. beclomethasone inhalers Qvar, Clenil	Yes	No	
	Prescribe by brand	Prescribe by generic	
For modified release preparations are the products non-interchangeable? e.g. mesalazine MR, diltiazem MR, nifedipine MR	Yes	No	
	Prescribe by brand	Prescribe by generic	
Are there important differences in the formulations between brands of the same medicine? e.g. buprenorphine and fentanyl patches	Yes	No	
	Prescribe by brand	Prescribe by generic	

	T	I I
Do the administration devices have different instructions for use AND patient familiarity with one product is important?	Yes	No
e.g adrenaline autoinjectors, inhalers	Prescribe by brand	Prescribe by generic
Does the product have more than one ingredient and the brand name helps identification? e.g. combined oral	Yes	No
contraceptives, hormone replacement therapy, emollients	Prescribe by brand	Prescribe by generic
Are there different licensed indications for the same drug?		
e.g. liraglutide as Victoza® or Saxenda®.	Yes	No
	Prescribe by brand	Prescribe by generic
Is the product a biological rather than chemical entity? e.g. erythropoietin, insulin glargine	Yes	No No
Door the ICD recommend	Prescribe by brand	Prescribe by generic
Does the ICB recommend prescribing a particular brand/branded generic? ** e.g. vitamin D (Hux D3®), quetiapine XL (Sondate XL®) oxycodone MR Oxypro MR®, melatonin products ** Only as agreed with the NEL Formulary and Pathways group and Integrated Medicines Optimisation and Prescribing Committee.	Yes Prescribe by brand/branded generic	No Prescribe by generic
Are there specific shortages of medicines which require a particular product to be prescribed temporarily to prevent disruption to the patient's treatment?	Yes Prescribe the specific product	No Prescribe by generic
a dationt:	available. Remember to revert to original product once back in stock.	

^{*}Should legitimate clinical needs require a specific brand then the brand should be provided on the NHS. Prescribers should be sure that the clinical needs are legitimate. Where there are affirmed reports of a specific preparation unexpectedly being ineffective or causing unexpected adverse effects, these should be reported to the MHRA (via the yellow card reporting site).

Examples of medicines which should be prescribed by brand (this list is not exhaustive, please refer to the BNF or SPS):

Allergy and immunology	Anaesthesia and pain	Cardiovascular	Endocrinology	Gastrointestinal
Adrenaline	Opioid patches: buprenorphine and fentanyl	Metolazone Diltiazem MR Nifedipine MR Enoxaparin	Insulins	Mesalazine
	Opioids MR: morphine, oxycodone, tramadol			
Mental health	Neurology	Organ transplantation	Respiratory	
Lithium Methylphenidate MR Antipsychotic depot injections, namely Zuclopenthixol decanoate, Paliperidone, Risperidone	Antiepileptics for epilepsy: Phenytoin, carbamazepine, phenobarbital Primidone For detailed list and categories see MHRA	Ciclosporin Tacrolimus	Inhalers: Beclometasone Budesonide Fluticasone	

References:

Specialist Pharmacy Service, Prescribing by generic or brand name in primary care published 27.3.22, last updated 13.9.22 https://www.sps.nhs.uk/articles/prescribing-by-generic-or-brand-name-in-primary-care/ accessed 16.3.23

NELFT Pharmacy Department, June 2023.

With special thanks and acknowledgement to Hambleton, Richmondshire and Whitby CCG, Harrogate and Rural District CCG and Scarborough and Ryedale CCG, original document adapted and can be found here: https://northyorkshireccg.nhs.uk/wp-content/uploads/2021/03/ny-brand-and-generic-prescribing-policy-2019-v1.000.pdf

Also, special thanks and acknowledgement to Herts Valleys CCG, Guidance for appropriate prescribing of generic and branded medicines, April 2017, https://hertsvalleysccg.nhs.uk/application/files/6015/3633/1968/FINAL Guidance for Appropriate prescribing of generic and branded medicines May 17.pdf